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Abstract
Carbohydrate-binding agents (CBAs) are potential HIV microbicidal agents with a high genetic barrier to
resistance. We wanted to evaluate whether two mannose-specific CBAs, recognizing multiple and often distinct
glycan structures on the HIV envelope gp120, can interact synergistically against HIV-1, HIV-2, and HIV-1
strains that were selected for resistance against particular CBAs [i.e., 2G12 mAb and microvirin (MVN)]. Paired
CBA/CBA combinations mainly showed synergistic activity against both wild-type HIV-1 and HIV-2 but also
2G12 mAb- and MVN-resistant HIV-1 strains as based on the median effect principle with combination indices
(CIs) ranging between 0.29 and 0.97. Upon combination, an increase in antiviral potency of griffithsin (GRFT) up
to *12-fold (against HIV-1), *8-fold (against HIV-2), and *6-fold (against CBA-resistant HIV-1) was observed.
In contrast, HHA/GNA combinations showed additive activity against wild-type HIV-1 and HIV-2 strains, but
remarkable synergy with HHA and GNA was observed against 2G12 mAb- and MVN-resistant HIV-1 strains
(CI, 0.64 and 0.49, respectively). Overall, combinations of GRFT and other CBAs showed synergistic activity
against HIV-1, HIV-2, and even against certain CBA-resistant HIV-1 strains. The CBAs tested appear to have
distinct binding patterns on the gp120 envelope and therefore do not necessarily compete with each other’s
glycan binding sites on gp120. As a result, there might be no steric hindrance between two different CBAs in
their competition for glycan binding (except for the HHA/GNA combination). These data are encouraging for
the use of paired CBA combinations in topical microbicide applications (e.g., creams, gels, or intravaginal rings)
to prevent HIV transmission.
Introduction
The HIV envelope glycoprotein gp120 is highly glyco-sylated and N-linked glycans account for *50% of
its molecular mass.1,2 The high-mannose and hybrid-type
N-glycans on gp120 contain a(1,2), a(1,3), and a(1,6) mannose
(Man) bridges and are thus considered as interesting targets
for mannose-specific carbohydrate-binding agents (CBAs).3
CBAs are proposed as potential microbicidal agents as they
inhibit (1) cell-free HIV replication, (2) cell–cell transmission
between HIV-infected and HIV-uninfected CD4 + T cells, (3)
capture of HIV by DC-SIGN-expressing cells, and (4) subse-
quent transmission to CD4 + target T cells.3
Natural CBAs are present in various species such as
prokaryotes, plants, invertebrates, and vertebrates. The
mannose-specific plant lectins Hippeastrum hybrid aggluti-
nin (HHA) and Galanthus nivalis agglutinin (GNA) pre-
dominantly recognize, respectively, a(1,3) or a(1,6)Man
and a(1,3)Man structures on gp120.4 One of the most
potent and broad-spectrum plant-derived anti-HIV-1 CBA
is BanLec, a jacalin-related CBA isolated from the banana
Musa acuminata; however, it also showed mitogenic activ-
ity.5 Griffithsin (GRFT), another mannose-specific CBA
originally isolated from the red algae Griffithsia sp., shows
a very potent and broad-spectrum anti-HIV-1 activity in
the picomolar range,6,7 as well as an outstanding safety
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and efficacy profile.8 The prokaryotic lectin microvirin
(MVN) targets a(1,2)Man residues on the viral envelope
and showed an anti-HIV-1 activity that is comparable to
the well-studied microbicidal drug candidate cyanovirin-N
(CV-N), but has a better safety profile.9 The neutralizing
mAb 2G12 was isolated from the blood of an HIV-infected
patient and also targets a(1,2)Man structures.10,11 The
discovery that the monoclonal antibody (mAb) 2G12
targets N-linked glycans present on gp120 revealed
that these glycans are interesting targets for neutralizing
antibodies.11,12
Antiretroviral drug resistance is one of the major reasons
for anti-HIV therapy failure and the spread of resistant viral
strains. To control and eventually diminish the HIV pan-
demic, novel prevention strategies are necessary. Therefore,
self-administered topical preexposure prophylaxis (PrEP)
measures such as vaginal and rectal gels, creams, and vari-
ous intravaginal ring (IVR) systems with sustained or con-
trolled release of substances13 would be very helpful tools.
While gels mainly are being evaluated at the moment for
further use,14,15 studies with an IVR system containing the
nonnucleoside reverse transcriptase inhibitor dapivirine also
showed a safe and good pharmacokinetic profile.16–18 Effi-
cient prevention by topical/systemic microbicides will, as
for the treatment of HIV infections, likely necessitate a
combination of drugs. A silicone IVR loaded with dapivirine
and the CCR5 antagonist maraviroc is now undergoing
preclinical investigations (MTN 013/IPM 026). The focus on
prevention methods against novel HIV infections is mainly
on HIV-1. HIV-2 receives less attention but is predominantly
found in West-African countries (such as Guinea-Bissau,
Ivory Coast), and has also been reported in parts of Europe,
America, and Asia as well.19 Although having lower trans-
mission efficiency and a slower disease progression compared
to HIV-1,20,21 in late stage disease a similarly high mortality
is noted.22 The antiviral therapeutic or prophylactic options
against HIV-2 have been less investigated. All first-generation
nonnucleoside reverse transcriptase inhibitors (e.g., efavirenz),
some protease inhibitors (e.g., amprenavir), and some entry
inhibitors (e.g., enfuvirtide) have strongly reduced or no anti-
HIV-2 activity.23
Here, we focus on the most potent mannose-specific CBAs
described to date (Table 1) and investigated whether the
combination of two mannose-specific CBAs (in particular
GRFT or MVN in combination with other CBAs), recognizing
multiple and often different glycans on gp120, can behave
synergistically against HIV-1, HIV-2, and CBA-resistant
HIV-1 replication.
Materials and Methods
Compounds and monoclonal antibodies
GRFT was isolated and purified as described elsewhere.24
BanLec was produced in Escherichia coli (M. Swanson et al.,
unpublished observations). MVN was a kind gift from Prof.
Dr. Elke Dittmann and Dr. Jan-Christoph Kehr (University of
Potsdam, Germany), and the mannose-specific plant lectins
HHA and GNA were ordered from E.Y. Laboratories Inc. (San
Mateo, CA). The nucleotide reverse transcriptase inhibitor
tenofovir was obtained from Gilead Sciences (Foster City,
CA). The mAbs 2G12 and b12 were obtained from Polymun
Scientific (Vienna, Austria).
Cell lines and cell cultures
MT-4 cells were a gift from Dr. L. Montagnier (at that time at
the Pasteur Institute, Paris, France) and cultured in RPMI-1640
medium supplemented with 10% FCS (Hyclone, Perbio Science,
Aalst, Belgium) and 2 mM l-glutamine (Invitrogen, Merelbeke,
Belgium) at 37C in a 5% CO2 controlled atmosphere.
Peripheral blood mononuclear cells (PBMCs) from healthy
donors were isolated out of buffy coats using Lymphoprep
(density: 1.077 g/ml) (Nycomed, Oslo, Norway), obtained
from the Blood Transfusion Centre (UZ Leuven, Belgium).
PBMCs were cultured in RPMI-1640 containing 10% FCS,
2 mM l-glutamine, and 2 ng/ml interleukin (IL)-2 (Roche
Molecular Biochemicals, Indianapolis, IN). The cells were
activated with 2 lg/ml PHA (Sigma-Aldrich, Bornem, Bel-
gium) for 3 days before infection with HIV-1 BaL.
Viruses
The HIV-1 R5 strain BaL and X4 strain NL4.3 were obtained
through the AIDS Research and Reference Reagent Program
(Division of AIDS, NIAID, NIH). The in vitro generation of the
HIV-1 strains NL4.32G12res (2G12 mAb-resistant NL4.3 HIV-1
strain) and NL4.3MVNres (microvirin-resistant NL4.3 HIV-1
strain) was described earlier.9,25 The HIV-2 strain ROD was
originally obtained from the Medical Research Council (MRC;
London, UK).
Antiviral assays
The anti-HIV-1 and anti-HIV-2 activity of each compound,
alone and in combination, in MT-4 cell cultures was deter-
mined by a tetrazolium-based colorimetric assay.26 Briefly,
3-fold dilutions of various test compounds were added in a
96-well plate and preincubated for 20 min at 37C with MT-4
cells (1 · 106 cells/ml). Next, various concentrations of virus
(NL4.3 wild-type, NL4.32G12res, NL4.3MVNres, and HIV-2
ROD) were given depending on the TCID50 of the virus stock.
Five days postinfection, cytopathic effects (CPE) were scored
microscopically and antiviral activity was measured by MTS/
PES using a Spectramax 96-well plate reader (Molecular De-
vices) as described previously.26,27
PHA-stimulated PBMCs were resuspended in cell culture
medium supplemented with 2 ng/ml IL-2 and seeded
(2.5 · 106 cells/ml) in 48-well plates (Iwaki Glass, Iwaki,
Japan) containing various concentrations of test compounds.
After 20 min of preincubation at 37C, infection with HIV-1 BaL
(500 pg/ml) occurred. IL-2 was added at days 3 and 6
Table 1. Mannose Specificity of the Carbohydrate-
Binding Agents Used in This Study
CBAs Molecular weight Sugar specificity
HHA 50 kDa a(1,3)-a(1,6)Man
GNA 50 kDa Mana(1,3)Man
2G12 mAb *150 kDa Mana(1,2)Man
MVN 14.3 kDa Mana(1,2)Man
BanLec 30 kDa High-mannose
GRFT 24.4 kDa High-mannose
CBAs, carbohydrate-binding agents; HHA, Hippeastrum hybrid
agglutinin; GNA, Galanthus nivalis agglutinin; mAb, monoclonal
antibody; Man, mannose; MVN, microvirin; BanLec, banana lectin;
GRFT, griffithsin.
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postinfection. Supernatant was collected at day 10 and viral
replication was measured using HIV-1 p24 Ag ELISA (Perkin
Elmer, Zaventem, Belgium) according to the manufacturer’s
guidelines.
Synergy analysis
Combination indices (CI) were calculated using the Cal-
cuSyn software (Biosoft, Cambridge, UK) based on the me-
dian effect principle of Chou and Talalay28 whereby CI < 0.9
are being synergistic, 0.9 < CI < 1.1 are additive, and CI > 1.1
are antagonistic.
Results
GRFT/CBA combinations demonstrate potent inhibition
against X4 HIV-1 NL4.3 infection
GRFT, MVN, mAb 2G12, BanLec, HHA, GNA, and the
CD4 binding site (bs)-targeting mAb b12 were first tested
individually, as single agents, and afterward in combination
with other CBAs against X4 HIV-1 NL4.3 replication in MT-4
T cell cultures. The 50% effective concentration (EC50s) for
each agent alone and in combination against HIV-1 repli-
cation are shown in Table 2. For GRFT, the EC50s were in the
lower nM range between 0.048 and 0.075 nM and up to 3-fold
and 7-fold reductions in the GRFT and the combined in-
hibitor concentrations were observed in a two-drug combi-
nation study to keep equally potent antiviral activities (Table
2). The most potent synergistic combinations were GRFT/
2G12 mAb and GRFT/b12 mAb with combination indices
(CIs) of 0.36 – 0.05 and 0.44 – 0.08, respectively (Fig. 1A and
Table 2). Synergism against X4HIV-1 NL4.3 was also noticed
with GRFT/MVN and GRFT/BanLec, as observed by the
leftward shift of the dose-dependent curves in the drug
combinations compared to single drug treatment (Fig. 1B
and C).
A comparable observation in EC50 value decrease and CI
determination was made for the CBA MVN (Table 2). Com-
bination with the carbohydrate binding mAb 2G12 and the
CD4bs-targeting mAb b12 resulted in potent cooperative
synergistic protection with CIs of 0.29 – 0.04 and 0.56 – 0.11 for
the combinations of MVN/2G12 mAb and MVN/b12 mAb,
respectively (Table 2).
When evaluating HHA in combination with GRFT (CI,
0.71 – 0.13), MVN (CI, 0.96 – 0.07), or GNA (CI, 1.31 – 0.14),
moderate synergy to nonsynergistic interactions were ob-
served (Table 2 and Fig. 1D).
Synergistic activity of GRFT/CBA combinations
against R5 HIV-1 BaL
Next, we investigated the potential synergistic effects
of GRFT and other CBAs against the R5 HIV-1 strain BaL
in peripheral blood mononuclear cell (PBMC) cultures.
GRFT inhibits HIV-1 BaL replication with a mean EC50 of
0.20 – 0.05 nM. In the GRFT/2G12 mAb combination (Fig. 2A),
up to 12-fold less GRFT and 2G12 mAb were needed to inhibit
HIV-1 BaL replication. Reduced EC50s from 0.20 – 0.05 nM to-
ward 0.014 – 0.005 nM for GRFT ( p = 0.08) and from
0.89 – 0.72 lg/ml towards 0.067 – 0.02 lg/ml for 2G12 mAb
( p = 0.3) were observed after combination. When the combi-
nation index was determined, a CI value of 0.48 – 0.12 was














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CBA COMBINATIONS WITH POTENT ANTI-HIV ACTIVITY 1515
34.5 – 9.6 nM. In combination with GRFT, a 2-fold decrease to
19.0 – 4.3 nM was observed for MVN ( p = 0.2) and a 3-fold de-
crease to 0.07 – 0.02 nM for GRFT ( p = 0.07) (Fig. 2B). Evaluation
of the GRFT/MVN combination showed a moderate syner-
gistic profile (CI value of 0.74 – 0.07; Fig. 3). A comparable de-
gree of synergism could be observed for the GRFT/BanLec
combination (CI, 0.77 – 0.05); however, its synergistic effect is
less pronounced, probably due to a weak but significant mi-
togenic activity of BanLec on PBMCs (Figs. 2C and. 3).
The observed EC50 of HHA against HIV-1 BaL was
76.1 – 6.5 nM. In combination with GRFT and GNA, additive
effects or weak antagonistic effects (CI, 0.97 – 0.04 and
1.10 – 0.10, respectively) were observed (Figs. 2D and 3).
Potent anti-HIV-2 activity of GRFT and BanLec alone
and in combination with other anti-HIV drugs
No data have been reported on the anti-HIV-2 activity of
GRFT and BanLec. Therefore, we evaluated the antiviral ac-
tivity of GRFT and BanLec as a single agent, and in combi-
nation with the CBAs HHA, MVN, and 2G12 mAb against
HIV-2 ROD replication in MT-4 cell cultures (Table 3). HIV-2
ROD was susceptible to GRFT and BanLec with a mean EC50
of 0.17 – 0.02 nM and 0.13 – 0.01 nM, respectively. When
GRFT was combined with BanLec or with HHA, a significant
5-fold increase in antiviral activity was noted for GRFT up to
46 pM, whereby both combinations resulted in a synergistic
inhibitory profile with CI values varying between 0.42 and
0.84 (Table 3 and Fig. 4A).
Next, we investigated whether the CBAs 2G12 mAb and
MVN, which have very weak, if any anti-HIV-2 activity,9
could enhance the antiviral activity of GRFT on HIV-2 repli-
cation. The lack of a dose-dependent effect of 2G12 mAb and
MVN makes the calculation of a combination index impossi-
ble,28 but as shown in Fig. 4B and C, neither 2G12 mAb nor
MVN seems to have any beneficial effect on the antiviral ac-
tivity of GRFT. No dose reductions in GRFT concentrations
were observed (and vice versa). Finally, when the plant lectins
HHA and GNA were combined to inhibit HIV-2 replication,
an additive antiviral effect was observed (Fig. 4D and Table 3).
Anti-HIV-2 activity of combinations of GRFT
with tenofovir and mAb b12
Additionally, we investigated whether synergism occurred
between CBAs and the clinically widely used anti-HIV-1 re-
verse transcriptase inhibitor (RTI) tenofovir and the CD4bs-
targeting mAb b12. As shown in Table 3, combining GRFT
and tenofovir increased their antiviral potency and resulted in
a pronounced synergistic drug–drug profile with a CI of
FIG. 1. Dose-dependent effect curves of CBA combinations against X4 HIV-1 NL4.3 replication in MT-4 cells. Prior to
infection with X4 HIV-1 NL4.3, MT-4 cells were pre-incubated with GRFT, 2G12 mAb, MVN, BanLec, HHA or GNA alone
and in combination for 20 minutes. The dose-response curves for GRFT/2G12 mAb (A), GRFT/MVN (B), GRFT/BanLec (C)
and HHA/GNA (D) are shown. The green squares and blue triangles show the dose-dependent effects of each CBA
individually and the red circles their combinations. The decrease in EC50s of each CBA after combination and also the degree
of synergism can be seen in the shift to the left of the red line towards the Y-axis. One representative experiment out of 5
separate experiments is shown. CBA, carbohydrate-binding agent.
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FIG. 2. Dose-dependent effect plots of CBA combinations in PBMCs infected with R5 HIV-1 BaL. PBMCs were infected with
R5 HIV-1 BaL after pre-incubation with GRFT, 2G12 mAb, MVN, BanLec, HHA or GNA alone and in combination. Viral
replication was measured by p24 HIV-1 Ag ELISA. The green bars represent the dose-dependent effect of GRFT (panels A–C)
and HHA (panel D). The blue bars show the effects of 2G12 mAb (A), MVN (B), BanLec (C) and GNA (D). The effect of the dual
CBA combinations is represented in yellow and the red bar shows the % p24 Ag HIV-1 production in untreated conditions
(positive control). The mean values out of 2–4 separate PBMC donor experiments are shown.
FIG. 3. Combination index (CI) de-
termination in PBMCs after infection
with R5 HIV-1 BaL. Synergism, ad-
ditivity or antagonism of 2-drug combi-
nations were calculated using CalcuSyn,
whereby CI < 0.9 are synergistic;
0.9 < CI < 1.1 are additive and CI > 1.1 are
antagonistic. The GRFT/2G12 mAb
combination showed the most potent
synergistic interaction, while GRFT/
MVN and GRFT/BanLec were mod-
erately synergistic. GRFT/HHA and
HHA/GNA combinations showed no
synergism. Mean CI-values – SEM of
2–4 PBMC donors are shown.
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0.54 – 0.05. As observed for the 2G12 mAb, b12 mAb lacks
anti-HIV-2 activity and therefore, again, no combination in-
dex could be determined.
Superior anti-HIV-1 activity of dual CBA combinations
against CBA-resistant HIV-1 strains.
First, we evaluated the effects of paired CBA combinations
against HIV-1 NL4.32G12res, lacking the N-glycan on position
295 (N295) of gp120.25 GRFT inhibited this strain with a mean
EC50 of 0.60 – 0.07 nM, while for HHA and BanLec an EC50 of
0.28 – 0.04 nM and 0.24 – 0.07 nM was noticed, respectively
(Table 4). In both combinations, similar (synergistic) combi-
nation indices were observed: CI of 0.64 – 0.10 for GRFT/
HHA and 0.62 – 0.15 for GRFT/BanLec (Table 4). When the
combination of GRFT with 2G12 mAb was evaluated, no
significant changes in the effective GRFT concentrations were
noticed. Due to the lack of a dose-dependent effect of 2G12
Table 3. Anti-HIV-2 Activity of Griffithsin (EC50 Values in nM) Alone and in Combination
with Other Anti-HIV Agents in MT-4 Cells
EC50 of agent 1 (nM) EC50 of agent 2 (nM)
Agent 1 Agent 2 Individual Combined
Dose
reduction p-value Individual Combined
Dose
reduction p-value CI Synergy
GRFT BanLec 0.19 – 0.02 0.038 – 0.005 5.0 0.0017 0.13 – 0.01 0.089 – 0.012 1.5 0.0853 0.84 – 0.08 + +
GRFT HHA 0.23 – 0.06 0.046 – 0.006 5.0 0.0317 6.4 – 0.4 3.9 – 0.5 1.6 0.0200 0.42 – 0.07 + + +
GRFT 2G12 mAba 0.13 – 0.05 0.10 – 0.02 1.3 0.6388 > 50a > 50a N.A. N.A.
GRFT MVN 0.11 – 0.02 0.12 – 0.05 1.1 0.8999 > 262 > 262 N.A. N.A
GRFT Tenofovir 0.24 – 0.02 0.030 – 0.006 8.0 0.0004 2000 – 500 1200 – 200 1.7 0.1969 0.54 – 0.05 + + +
GRFT b12 mAba 0.14 – 0.02 0.13 – 0.01 1.1 0.6608 > 50a > 50a N.A. N.A
HHA GNA 14.0 – 10.0 1.7 – 0.4 8.1 0.1992 3.2 – 1.6 1.7 – 0.4 1.8 0.3562 1.03 – 0.07 Additive
aConcentrations of the mAbs 2G12 and b12 are expressed in lg/ml. Dose reduction is the reduction in inhibitor concentration after
combination compared to single drug treatment. Combination index: CI represented by the mean – SEM from up to four independent
experiments, whereby CI < 0.9 indicates synergism, 0.9 < CI < 1.1 indicates additivity, and CI > 1.1 indicates antagonism. The degree of synergy
is calculated at the EC95 level with + , slight synergism (CI: 0.85–0.90); + + , moderate synergism (CI: 0.70–0.85); + + + , synergism (CI: 0.30–
0.70); and + + + + , strong synergism (CI: 0.10–0.30). A p-value with p < 0.05 is considered significant. N.A., not applicable.
FIG. 4. Dose-dependent effect curves of CBA combinations on HIV-2 replication. Dose-dependent anti-HIV-2 effects for
GRFT/BanLec (A), GRFT/2G12 mAb (B), GRFT/MVN (C) and HHA/GNA (D) are shown. The green squares and blue
triangles, and the red circles indicate the antiviral activity of each CBA individually and their combination, respectively. The
observed leftwards shift is an indication for synergistic drug interactions. One representative experiment out of 4 is shown.
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mAb against the 2G12-resistant virus, a calculation of the CI
was not possible (Table 4). Remarkably, when HHA was
combined with GNA against the NL4.32G12res virus, a signif-
icant 2.5-fold increase in antiviral potency was noted for both
CBAs, resulting in a synergistic cooperative drug–drug in-
teraction profile (CI, 0.64 – 0.09; Fig. 5A and Table 4).
Finally, we investigated whether synergy occurred against
HIV-1 NL4.3MVNres that contains four N-glycan deletions on
gp120 at positions N295, N339, N386, and N396.9 As shown in
Table 4, a comparable, but more potent synergistic combina-
tion profile was observed against MVN-resistant HIV-1, with
CI-values < 0.50, and synergistic activity was found again for
the HHA and GNA combination (Fig. 5B and Table 4).
Discussion
An effective microbicide must have (1) a potent and pref-
erentially broad-spectrum antimicrobicidal activity, (2) lim-
ited to no toxicity on the vaginal or rectal epithelial cell layer,
and (3) a good pharmacokinetic/dynamic profile.29 Disrup-
tion of the epithelial layer increases the risk for sexually
transmitted diseases such as HIV and herpes simplex virus
type 2 (HSV-2).30 From all the diverse CBAs described so far,
GRFT is presumably the most potent and broad-spectrum
anti-HIV-1 entry inhibitor with an outstanding safety and
efficacy profile.6,8 Recombinant forms of GRFT, with no loss
of antiviral activity, can also be easily produced in E. coli and
in the Nicotiana benthamiana plant.24 Also BanLec ranks among
the most potent anti-HIV-1 lectins reported so far.5 Although
GRFT and BanLec have been reported to suppress a wide
variety of HIV-1 strains and clinical isolates, the HIV-2 in-
hibitory activity of GRFT and BanLec has not previously been
reported. When the efficacy of GRFT was evaluated against
HIV-2 (ROD) replication, a range of EC50 values between 110
and 240 pM was obtained (Table 3). These values of antiviral
activity were only 2- to 3-fold higher than those observed for
inhibition of HIV-1 (NL4.3), since the EC50s for HIV-1 (NL4.3)
varied between 48 and 75 pM (Table 2). When the anti-HIV-2
activity of BanLec was compared with HIV-1, no significant
differences in inhibitory concentrations were observed (EC50
of 0.20 – 0.05 nM for HIV-1 and 0.13 – 0.01 nM for HIV-2; Ta-
bles 2 and 4). Thus, both GRFT and BanLec efficiently sup-
press both HIV-1 and HIV-2 in the picomolar range.
In the search for an effective, safe, acceptable, and afford-
able microbicide, many potential microbicidal candidates
were tested alone or in combination with other (classes of )
antiretroviral drugs.31,32 However, no investigations were
performed on the effects on HIV replication when two drugs
belonging to the functional class of CBAs would be combined.
To evaluate synergistic drug–drug interactions, some re-
search groups propose to use ‘‘single-round’’ instead of
‘‘multiple-round’’ infection assays to evaluate synergy.33–35
Recently a paper by Ketas et al. was published that suggested
a modification of the classic synergy calculation by the
Chou and Talalay method as they used single-round infec-
tion and a nonlinear calculation model.33 Here, we used the
multiple-round virus infection to mimic more the real viral
life cycle and replication abilities in a CD4 + T cell line and
PBMCs.
It was interesting to observe synergistic anti-HIV activity
when GRFT was combined with any other CBA, irrespective





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CBA COMBINATIONS WITH POTENT ANTI-HIV ACTIVITY 1519
(MT-4, PBMC). Such synergistic potential of GRFT was also
kept against mutant HIV-1 strains that were (partially) resis-
tant to other CBAs. BanLec in combination with GRFT (or
MVN) also resulted in synergy. Although BanLec and GRFT
lost some of their antiviral activity (*10-fold) against the
HIV-1 NL4.32G12res and NL4.3MVNres strains compared to the
original wild-type HIV-1 NL4.3 virus (Tables 2 and 4), they
proved to be so exquisitely potent that they kept pronounced
antiviral activity against the drug-resistant virus strains and,
when combined, synergy is still observed. Based on these
data, GRFT as well as BanLec or any nonmitogenic derivative
thereof could be an interesting lead molecule for further
combined microbicidal development.
CV-N and MVN are both CBAs isolated from Cyano-
bacteria and have a similar gp120 sugar binding specificity,
directed against Mana(1,2)Man residues. CV-N has both po-
tent anti-HIV-1 and anti-HIV-2 activity, but also strong
cytokine-stimulatory and mitogenic activity.36,37 On the other
hand, MVN has comparable anti-HIV-1 activity to CV-N but a
much higher safety profile.9,38 Therefore we used MVN in-
stead of CV-N for exploring dual CBA combinations. In all,
except one (GRFT/HHA), dual MVN/CBA combinations,
synergistic activity was observed (Table 2 and Fig. 2B). The
additivity between GRFT and HHA can possibly be explained
by the sharing of a similar epitope on gp120 by both CBAs.
Strong synergism was observed between GRFT and many
other lectin CBAs as discussed above but also when combined
with the carbohydrate-binding mAb 2G12 (CI, 0.29 – 0.04),
although 2G12 mAb has a much lower antiviral activity as a
single agent compared to GRFT. Remarkably, while rather low-
dose reductions were observed in most of the evaluated dual
CBA combinations, the 2G12 mAb had a 9-fold dose reduction
in MT-4 cells and even up to 13-fold in PBMCs, which could
have potential benefits when it would be used in a combined
microbicidal gel application. These synergy data are in agree-
ment with recently published data on pseudo-typed HIV-1
using MVN and CV-N in combination with 2G12 mAb.38 As
also observed in Fig. 1A, the broadly neutralizing 2G12 mAb
did not completely block viral replication even at high doses
and thus may lead to the rapid appearance of resistant virus. In
fact, deletion of one specific glycan mutation at position 295
(N295) in gp120 proved sufficient to display full resistance to
2G12 mAb.25 Also, it has been demonstrated that the binding of
2G12 mAb to gp120 can be blocked by MVN and BanLec but
not vice versa as 2G12 mAb does not block the binding of MVN
or BanLec to gp120.5,9 These findings can be explained by the
assumption that the lectin CBAs can bind to several sugars on
gp120, whereas 2G12 mAb recognizes only one well-defined
sugar epitope. The incomplete suppression of virus replication
by 2G12 mAb and the subsequent risk of resistance develop-
ment are other arguments for combining 2G12 mAb with a
lectin CBA. Our data revealed not only full virus suppression in
such CBA/2G12 mAb drug combination experiments, but also
a pronounced synergistic antiviral activity. The observed syn-
ergy can have multiple explanations, i.e., targeting of multiple
but distinct gp120 (N-glycan) epitopes by different CBAs,
different time points of CBA interaction during the gp120/
gp41-CD4/CXCR4/CCR5 binding and fusion process, and/or
conformational changes in gp120 upon binding of one CBA
causing exposure of previously less available epitopes allowing
a more efficient binding by the other CBA. The synergy/
additivity between the CBAs can also be explained by subtle
differences in the CBA sugar specificity.
With the non-CBA mAb b12, targeting the CD4 binding site
on gp120, synergism occurred in combination with MVN and
GRFT (Table 2). Alexandre et al. showed that GRFT interacts,
among others, with the N-glycan at position 386 (N386) on
gp120, and exposes the CD4 binding site by binding to this
glycan. This allows a more tight interaction of the GRFT-
bound gp120 with the mAb b12, which may explain the
synergistic activity.39 It could therefore be possible that a
similar mechanism of action is responsible for the observed
synergy between MVN and the non-CBA mAb b12. Our
generated HIV-1 NL4.3MVNres with a deleted N-linked glycan
on position 386 indeed demonstrated that N386 is a crucial
anchoring point for MVN.9
For actinohivin, a broadly neutralizing prokaryotic lectin, a
tight interaction with the envelope protein of SIV was demon-
strated by surface plasmon resonance technology, but it lacked
anti-SIV activity in several viral replication assays.40 These data
revealed that binding of CBAs to gp120 glycans may occur, but
these are not always necessarily in neutralizing viral replication.
FIG. 5. Synergy of HHA/GNA against NL4.32G12res and NL4.3MVNres HIV-1 strains. Dose-dependent effects of HHA/GNA
combinations against NL4.32G12res (A) and NL4.3MVNres (B). The green triangles show the HHA concentration, the blue
squares the GNA concentration and the red circles their combined effect. Their increase in antiviral potency and thus
leftwards shift indicates in a synergistic profile. One representative experiment out of 4 separate experiments is shown.
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Based on these findings, we investigated whether the CBAs
2G12 mAb and MVN, which both lack anti-HIV-2 activity,
could influence the anti-HIV-2 activity of GRFT by binding to
gp120 and triggering conformational changes in the envelope
that may influence GRFT binding and eventual antiviral effi-
cacy or vice versa. However, no increase or decrease in the anti-
HIV-2 effect of GRFT was seen in the paired drug combinations
(Fig. 4B and C). Neither did binding of GRFT to gp120 induce
conformational changes throughout gp120 that led to a gain of
anti-HIV-2 activity for MVN or 2G12 mAb.
In contrast to most other paired CBA combinations, no
synergy was observed between HHA and GNA against the
wild-type HIV-1 strains NL4.3 (X4) and BaL (R5) and against
HIV-2 ROD (Figs. 1–4 and Table 3). Instead, against the
NL4.32G12res and NL4.3MVNres HIV-1 strains, HHA/GNA
clearly showed synergistic interactions (Fig. 5 and Table 4).
Both HHA and GNA are tetrameric plant lectins with a rather
high molecular weight (50 kDa). These agents recognize
structurally comparable N-glycans on gp120, namely a(1,3)
and a(1,6)Mannose residues,3 which seems to result in an
additive combinatory drug profile. Surprisingly, HIV-1
NL4.32G12res virus was strikingly more susceptible to the CBAs
HHA and GNA than wild-type virus.25 This peculiar phe-
nomenon is again shown here when both CBAs were com-
bined, resulting in a *10-fold decrease of HHA concentration
from 3.8 nM to 0.37 nM and a 35-fold decrease of GNA con-
centration from 15 nM to 0.43 nM (Tables 2 and 4). The deleted
N-glycans in the mutant gp120 of the CBA-resistant virus
strains may create ‘‘holes’’ in the N-glycan shield and/or con-
formational changes on the surface of gp120 resulting in a
better ‘‘binding site’’ for certain high-molecular-weight CBAs
such as HHA and GNA to allow synergy.
The microbicide 1% tenofovir gel study (CAPRISA 004)
revealed a reduced transmission of HIV-1 but also of HSV-2
by 39% and 51%, respectively.41 The latest results of the
VOICE (Vaginal and Oral Interventions to Control the Epi-
demic) study (MTN-003) were less optimistic. The oral teno-
fovir tablet and tenofovir gel arms of VOICE were dropped
following interim reviews of data that determined neither
product was effective in the women assigned to those study
groups. Adherence seemed to be the major problem, although
many other questions remain.
A recent study has shown that tenofovir inhibits HSV-2
infections by targeting the herpetic DNA polymerase,42 which
was made possible by the high local tenofovir concentrations
that were afforded by the topical drug delivery. A microbicide
drug with such a dual mechanism of antiviral (i.e., HIV and
HSV) action is beneficial in terms of clinical application since
HSV-2 is considered as an important copathogen that may
accelerate HIV transmission in HIV-exposed individuals. In-
terestingly, besides its potent anti-HIV activity, GRFT also
inhibits HSV-2 (K.E. Palmer et al., unpublished observations).
Since we could show that tenofovir acts synergistically with
various CBAs including GRFT, MVN, and BanLec,43,44 a
GRFT/tenofovir combination gel may become a very at-
tracting microbicide formulation to diminish HIV-1 and HIV-2
but also HSV-2 transmission worldwide. Additionally, due to
the potent anti-HCV activity of GRFT and other CBAs, such
agents could even be able to reduce the number of novel
(co)infections with HCV.45,46 Within the scope of the topical
PrEP perspective, the CBAs have the benefit of their broad
antiviral activity, and by strongly binding to the glycans on
gp120 as a virucide they target HIV in the lumen of the vagina
before genital tissue penetration can occur. In addition, they
have also the advantage of a high genetic barrier to resistance
and do not need cellular uptake as well as activation/modi-
fication to gain anti-HIV activity (e.g., the RTI tenofovir). Even
the important DC-SIGN-mediated pathway (HIV capture and
transmission to susceptible CD4 + T cells) can be completely
blocked by this class of inhibitors.3,47
The first trials in macaques using gel-formulated CV-N
applied vaginally and rectally showed promising results as it
potently inhibited SHIV transmission.48,49 More recently, a
63% reduction in SHIV transmission was observed when
macaques were treated with a CV-N-expressing Lactobacillus
strain.50 Given the many failures in clinical trials of poly-
anionic antivirals (e.g., nonoxynol-9 and PRO2000),51,52 which
also target HIV in the lumen of the vagina, the class of CBAs
(especially GRFT) could contribute to novel perspectives in
the field of PrEP.
In conclusion, our study has shown synergistic antiviral
(HIV-1/HIV-2) activity when dual combinations of CBAs
were exposed to virus-infected cell cultures, irrespective of the
nature of the virus (X4, R5) and cell type (MT-4, PBMC). Also,
virus strains containing N-glycan deletions in their envelope
often maintain high sensitivity to the synergistic CBA com-
binations. These data are very encouraging in the search for
the development of efficient drug pairs to be combined for
microbicide treatment.
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